Literature DB >> 35958458

UBE2L3 promotes lung adenocarcinoma invasion and metastasis through the GSK-3β/Snail signaling pathway.

Xingjie Ma1, Weibo Qi1, Fan Yang1, Huan Pan2.   

Abstract

Lung cancer is the leading cause of cancer-related mortality, and the deaths are mostly attributed to distant metastasis. Previous studies have demonstrated that ubiquitin-conjugating enzyme E2 L3 (UBE2L3) mediates the progression of many human cancers. However, the roles and molecular mechanisms of UBE2L3 in invasion and metastasis of lung adenocarcinoma (LUAD) are yet to be fully understood. Here, we studied the expression pattern of UBE2L3 and demonstrated that it is dramatically up-regulated in LUAD tissues compared with the normal tissues, and its overexpression is positively correlated with lymph node metastasis. Moreover, the upregulation of UBEE2L3 in LUAD tissues is associated with shorter overall survival (OS). UBE2L3 silencing impairs the metastatic capacity of LUAD cells in vitro and in vivo, while its overexpression confers an opposite effect. In addition, our data showed that UBE2L3 promotes cancer cells epithelial-mesenchymal transition (EMT) and metastasis via the glycogen synthase kinase 3β (GSK-3β)/Snail axis. Besides, UBE2L3 was shown to promote ubiquitination and degradation of the GSK-3β. Immunohistochemical analysis demonstrated that UBE2L3 expression is positively correlated with Snail, but negatively correlated with GSK-3β and E-cadherin in LUAD tissues. Taken together, our findings demonstrated that UBE2L3 modulates metastasis of LUAD cells. AJTR
Copyright © 2022.

Entities:  

Keywords:  EMT; GSK-3β; Lung adenocarcinoma; Snail; metastasis

Year:  2022        PMID: 35958458      PMCID: PMC9360901     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   3.940


  31 in total

Review 1.  The EMT regulator slug and lung carcinogenesis.

Authors:  Jin-Yuan Shih; Pan-Chyr Yang
Journal:  Carcinogenesis       Date:  2011-06-10       Impact factor: 4.944

Review 2.  The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.

Authors:  Barbara Melosky; Paul Wheatley-Price; Rosalyn A Juergens; Adrian Sacher; Natasha B Leighl; Ming-Sound Tsao; Parneet Cheema; Stephanie Snow; Geoffrey Liu; Paul B Card; Quincy Chu
Journal:  Lung Cancer       Date:  2021-06-05       Impact factor: 5.705

3.  HMGA2 induces transcription factor Slug expression to promote epithelial-to-mesenchymal transition and contributes to colon cancer progression.

Authors:  Yang Li; Zhongxin Zhao; Chuanhui Xu; Zhuqing Zhou; Zhe Zhu; Tiangeng You
Journal:  Cancer Lett       Date:  2014-09-11       Impact factor: 8.679

4.  Genomic Alteration During Metastasis of Lung Adenocarcinoma.

Authors:  Qiang Tan; Jian Cui; Jia Huang; Zhengping Ding; Hao Lin; Xiaomin Niu; Zhiming Li; Guan Wang; Qingquan Luo; Shun Lu
Journal:  Cell Physiol Biochem       Date:  2016-02-01

5.  GSK3β overexpression indicates poor prognosis and its inhibition reduces cell proliferation and survival of non-small cell lung cancer cells.

Authors:  Jing Zeng; Dan Liu; Zhixin Qiu; Yi Huang; Bojiang Chen; Lei Wang; Huan Xu; Na Huang; Lunxu Liu; Weimin Li
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

6.  Ubiquitin conjugating enzyme E2 L3 promoted tumor growth of NSCLC through accelerating p27kip1 ubiquitination and degradation.

Authors:  Xingjie Ma; Junjie Zhao; Fan Yang; Haitao Liu; Weibo Qi
Journal:  Oncotarget       Date:  2017-08-24

7.  HP1γ Sensitizes Cervical Cancer Cells to Cisplatin through the Suppression of UBE2L3.

Authors:  Sang Ah Yi; Go Woon Kim; Jung Yoo; Jeung-Whan Han; So Hee Kwon
Journal:  Int J Mol Sci       Date:  2020-08-19       Impact factor: 5.923

8.  Long non-coding RNA LINC01116 acts as an oncogene in prostate cancer cells through regulation of miR-744-5p/UBE2L3 axis.

Authors:  Shengjie Yu; Huihong Yu; Yuanfeng Zhang; Chuan Liu; Weili Zhang; Yunyun Zhang
Journal:  Cancer Cell Int       Date:  2021-03-16       Impact factor: 5.722

Review 9.  Cell death-based treatment of lung adenocarcinoma.

Authors:  Tatiana V Denisenko; Inna N Budkevich; Boris Zhivotovsky
Journal:  Cell Death Dis       Date:  2018-01-25       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.